Characterization of the overall survival benefit in ENCORE 301, a randomized, placebo-controlled phase II study of exemestane with and without entinostat in ER+ postmenopausal women with metastatic breast cancer.

Authors

Pamela Klein

PMK Consulting

Pamela Klein , William McCulloch , Peter Ordentlich , Scott Cruickshank , Miranda Rees , Denise Yardley

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2017 ASCO Annual Meeting

bookmark_border

A phase II, multicenter, randomized trial of eribulin plus gemcitabine (EG) vs. paclitaxel plus gemcitabine (PG) in patients with HER2-negative metastatic breast cancer (MBC) as first-line chemotherapy (KCSG BR13-11, NCT02263495).

First Author: Kyung Hae Jung

insert_chart_outlined

Poster

2016 ASCO Annual Meeting

bookmark_border

Phase II trial of CC-486, a DNA methyltransferase inhibitor, in combination with fulvestrant in postmenopausal women with ER+, HER2- metastatic breast cancer who have progressed on an aromatase inhibitor (AI).

First Author: Mario Campone

insert_chart_outlined

Poster

2015 ASCO Annual Meeting

bookmark_border

Phase III study of Palbociclib in combination with Exemestane vs. Capecitabine, in Hormonal Receptor (HR) positive/HER2 negative Metastatic Breast Cancer (MBC) patients with Resistance to non-steroidal Aromatase inhibitors (NSAI): PEARL study (GEICAM/2013-02_CECOG/BC.1.3.006)

First Author: Miguel Martin

insert_chart_outlined

Poster

2014 ASCO Annual Meeting

bookmark_border

Randomized phase 2 study of abiraterone acetate (AA) with or without exemestane (E) in postmenopausal patients (pts) with estrogen receptor–positive (ER+) metastatic breast cancer (MBC).

First Author: Joyce O'Shaughnessy